Cargando…

A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours

BACKGROUND: Poly adenosine diphosphate (ADP)-ribose polymerase (PARP) is essential in cellular processing of DNA damage via the base excision repair pathway (BER). The PARP inhibition can be directly cytotoxic to tumour cells and augments the anti-tumour effects of DNA-damaging agents. This study ev...

Descripción completa

Detalles Bibliográficos
Autores principales:	Khan, O A, Gore, M, Lorigan, P, Stone, J, Greystoke, A, Burke, W, Carmichael, J, Watson, A J, McGown, G, Thorncroft, M, Margison, G P, Califano, R, Larkin, J, Wellman, S, Middleton, M R
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2011
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3048218/ https://www.ncbi.nlm.nih.gov/pubmed/21326243 http://dx.doi.org/10.1038/bjc.2011.8

Ejemplares similares

The PARP inhibitor AZD2281 (Olaparib) induces autophagy/mitophagy in BRCA1 and BRCA2 mutant breast cancer cells
por: Arun, Banu, et al.
Publicado: (2015)

Synergetic Effects of PARP Inhibitor AZD2281 and Cisplatin in Oral Squamous Cell Carcinoma in Vitro and in Vivo
por: Yasukawa, Masaaki, et al.
Publicado: (2016)

A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma
por: Middleton, M R, et al.
Publicado: (2000)

O(6)-methylguanine-DNA methyltransferase depletion and DNA damage in patients with melanoma treated with temozolomide alone or with lomeguatrib
por: Watson, A J, et al.
Publicado: (2009)

Exclusion of the genes CDKN2 and PTEN as causative gene defects in Li–Fraumeni syndrome
por: Burt, E C, et al.
Publicado: (1999)

Sequential administration of varying doses of dacarbazine and fotemustine in advanced malignant melanoma.
por: Lee, S. M., et al.
Publicado: (1993)

2281 Prophylactic broad-spectrum antibiotics for childhood malnutrition
por: Langdon, Amy Elizabeth, et al.
Publicado: (2018)

A novel TP53 splicing mutation in a Li-Fraumeni syndrome family: a patient with Wilms' tumour is not a mutation carrier.
por: Varley, J. M., et al.
Publicado: (1998)

2281: Temperature regulating wheelchair cushion for prevention of pressure ulcers
por: Yavuz, Metin, et al.
Publicado: (2018)

Allelic imbalance of chromosome 6q in ovarian tumours.
por: Orphanos, V., et al.
Publicado: (1995)

2281. Trends in Antibiotic Prescriptions in U.S. Nursing Homes, 2018-2020
por: Vo, Quynh, et al.
Publicado: (2023)

Expression of Ku70 correlates with survival in carcinoma of the cervix
por: Wilson, C R, et al.
Publicado: (2000)

AZD1775 Increases Sensitivity to Olaparib and Gemcitabine in Cancer Cells with p53 Mutations
por: Meng, Xiangbing, et al.
Publicado: (2018)

PB2281: HOW TO AVOID FALSE-NEGATIVE AND FALSE-POSITIVE COVID-19 PCR TESTING
por: Fevraleva, I., et al.
Publicado: (2022)

Dosage and cycle effects of dacarbazine (DTIC) and fotemustine on O6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells.
por: Lee, S. M., et al.
Publicado: (1993)

AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity
por: Fok, Jacqueline H. L., et al.
Publicado: (2019)

005 OP: ENTREPRENEURIALISM, ADAPTATION, AND DISCRETION AMONG NURSES IN A TRANSNATIONAL COLLABORATION IN MALAWI AND TANZANIA
por: McGown, M
Publicado: (2017)

2281. Impact of the Introduction of the Haemophilus influenzae Type B Conjugate Vaccine in Southern India
por: Fitzwater, Sean, et al.
Publicado: (2018)

Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies
por: Eisen, T, et al.
Publicado: (2011)

ATR Inhibitor AZD6738 (Ceralasertib) Exerts Antitumor Activity as a Monotherapy and in Combination with Chemotherapy and the PARP Inhibitor Olaparib
por: Wilson, Zena, et al.
Publicado: (2022)

Interaction of the novel agent amphethinile with tubulin.
por: McGown, A. T., et al.
Publicado: (1989)

Q-TWiST analysis comparing ipilimumab/dacarbazine vs placebo/dacarbazine for patients with stage III/IV melanoma
por: Sherrill, B, et al.
Publicado: (2013)

Treatment of metastatic malignant melanoma with dacarbazine, vindesine and cisplatin.
por: Pectasides, D., et al.
Publicado: (1989)

Novel heterozygous deletion in the HNF1β gene - adolescent with antibody negative diabetes, longstanding hyperglycaemia without ketosis, cataracts, small echogenic kidneys with a cortical cyst, pancreatic atrophy, exocrine pancreatic insufficiency and a uterine anomaly
por: Conwell, Louise S, et al.
Publicado: (2015)

Phase I–II study of plitidepsin and dacarbazine as first-line therapy for advanced melanoma
por: Plummer, R, et al.
Publicado: (2013)

Dacarbazine Combined Targeted Therapy versus Dacarbazine Alone in Patients with Malignant Melanoma: A Meta-Analysis
por: Jiang, Guan, et al.
Publicado: (2014)

Meta-Analysis of the Safety and Efficacy of Interferon Combined With Dacarbazine Versus Dacarbazine Alone in Cutaneous Malignant Melanoma
por: Xin, Yong, et al.
Publicado: (2016)

ZNStress: a high-throughput drug screening protocol for identification of compounds modulating neuronal stress in the transgenic mutant sod1G93R zebrafish model of amyotrophic lateral sclerosis
por: McGown, Alexander, et al.
Publicado: (2016)

Sodium Taurocholate Micelles in Fluorometrix Analysis
por: McGown, Linda B., et al.
Publicado: (1988)

Phase III randomized study of fotemustine and dacarbazine versus dacarbazine with or without interferon-α in advanced malignant melanoma
por: Daponte, Antonio, et al.
Publicado: (2013)

2281. Ceftolozane–tazobactam (C/T) Treatment Outcomes in Immunocompromised (IC) Patients with Multidrug-Resistant (MDR) Pseudomonas aeruginosa (PA) Infections
por: Hart, Delaney E, et al.
Publicado: (2019)

Survival with dacarbazine and fotemustine in newly diagnosed glioblastoma multiforme
por: Fazeny-Dörner, B, et al.
Publicado: (2003)

EAF2 regulates DNA repair through Ku70/Ku80 in the prostate
por: Ai, J, et al.
Publicado: (2017)

Evaluation of protective effect of amifostine on dacarbazine induced genotoxicity
por: Etebari, M., et al.
Publicado: (2015)

Comparison of daunorubicin and anthrapyrazolone sensitivity and transport in resistant cell lines.
por: McGown, A., et al.
Publicado: (1987)

Isoflavones inhibit intestinal epithelial cell proliferation and induce apoptosis in vitro
por: Booth, C, et al.
Publicado: (1999)

SUN-270 Heterozygous Mutation in ABCC8 in a Pedigree with Congenital Hyperinsulinism, Multiple Macrosomic Stillbirths, and Adult-Onset Diabetes Mellitus
por: Ludwig, Karissa, et al.
Publicado: (2019)

Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma
por: Algazi, A P, et al.
Publicado: (2012)

The interaction with tubulin of a series of stilbenes based on combretastatin A-4.
por: Woods, J. A., et al.
Publicado: (1995)

Dacarbazine depletes the ovarian reserve in mice and depletion is enhanced with age
por: Winship, Amy L., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_b9k9cbphvn1m83jfcb1gnlpuif